Inflammatory bowel disease (IBD) includes two idiopathic syndromes, ulcerative colitis and Crohn's disease. In ulcerative colitis, inflammation is limited to the colonic mucosa and submucosa. Crohn's disease may, however, involve the small intestine, all bowel wall layers, and the upper gastrointestinal tract. Because health-related quality of life is significantly impaired during active disease, pharmaceutical care. is important in patient management. Traditional therapy includes 5-aminosalicylates, corticosteroids, and antimicrobial therapy. In steroid-resistant active disease, immunosuppressants (cyclosporine, azathioprine, 6-mercaptopurine, methotrexate) have a role but possess significant toxicity profiles. Current research focuses on the role of inflammatory mediators in IBD. Investigational therapies include monoclonal antibodies to proinflammatory cytokines, inhibitory cytokines, and anti-CD4 monoclonal antibodies.
Hastings Ge,Weber Rj..Inflammatory bowel disease: Part 1. Clinical features and diagnosis.Am Fam Physician. 1993;47:598-607
5.
Galperin C,Gershwin E..Immunopathogenesis of gastrointestinal and hepatobiliary diseases.JAMA. 1997;278:1946-1955
6.
Van Deventer Sj..Tumour necrosis factor and Crohn's disease.Gut. 1997;40 (4): 443-448
7.
Lukacs Nw,Chesnue Sw,Strieter R,Warmington K,Kunkel Sl..Inflammatory granuloma formation is mediated by TNF-α inducible intercellular adhesion molecule.J Immunol. 1994;152:5883-5889
8.
Hanauer Sb..Medical therapy of ulcerative colitis.Lancet. 1993;342:412-417
9.
Irvine Ej..Quality of life issues in patients with inflammatory bowel disease.Am J Gastroenterol. 1997;92 (12): 18-24S
10.
Akerkar Ga,Peppercorn Ma..Inflammatory bowel disease in the elderly: Practical treatment guidelines.Drugs. Aging. 1997;10 (3): 199-208
11.
Griffin Mg,Miner Pb..Conventional drug therapy in inflammatory bowel disease.Gastroenterol Clin North Am. 1995;24:509-517
12.
Pruzanski W,Stefanski E,Vadar P,Ramamurthy Ns..Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: A novel mechanism of anti-inflammatory activity.Biochem Pharmacol. 1997;53 (12): 1901-1907
13.
Drug Facts and Comparisons. Kastrup EkHebel SkRivard RBurnham ThShort Rm, ed. St. Louis, MO: Facts and Comparisons; 1999:
14.
14.McEvoyGKLitvakKWelshOhDeweyDrBollingerLa, et al., editors. AHFS Drug Information, American Society of Health-System Pharmacists, Bethesda, MD, 1998.
16.Azulfidine® (sulfasalazine) professional prescribing information.Pharmacia and Upjohn Company, Kalamazoo, MI, Jan1997.
17.
Clinical Pharmacology. Gold Standard Multimedia Inc.; 1994––1998:
18.
Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis: a randomized, double-blind, multi-center trial.Dig Dis Sci. 1987;32:598-602
19.
Gendre Jp,Mary Jy,Florent C,Modigliani R,Colombel Jf.Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID).Gastroenterology. 1993;104:435-439
20.
Dipiro Jt.Pharmacotherapy: A Pathophysiologic Approach. Stamford, CT: Appleton and Lange; 1997:
21.
Hanauer Sb,Schulman Mi..New therapeutic approaches.Gastroenterol Clin North Am. 1995;24:523-533
22.
Kirsner J,Shorter R.Trends in Inflammatory Bowel Disease. Philadelphia, PA: Lea and Febiger; 1988:51-64.
23.
Barbezat Go..Recent advances: Gastroenterology.Br Med J. 1998;316 (7125): 125-128
24.
Wagtmans Mj,Witte Amc,Taylor Dr,Biemond T,Veenendaal Ra.Low seroprevalence of helicobacter pylori antibodies in historical sera of patients with Crohn's disease.Scand J Gastroenterol. 1997;32 (7): 712-718
25.
Halme L,Karkkainen P,Rautelin H,Kosunen Tu,Sipponen P..High frequency of helicobacter negative gastritis in patients with Crohn's disease.Gut. 1996;38 (3): 379-383
26.
Parente F,Molteni P,Bollani S,Maconi G,Vago L.Prevalence of helicobacter pylori infection and related upper gastrointestinal lesions in patients with inflammatory bowel diseases: a cross-sectional study with matching.Scand J Gastroenterol. 1997;32 (11): 1140-1146
27.
Oberhuber G,Puspok A,Oesterreicher C,Novacek G,Zauner C.Focally enhanced gastritis: a frequent type of gastritis in patients with Crohn's disease.Gastroenterology. 1997;112 (3): 698-706
28.
Gorbach Sl,Tabagchali S..Bacteria, bile and the small bowel.Gut. 1969;10:963-971
29.
Arndt H,Palitzsch K,Grisham M,Granger N..Metronidazole inhibits leukocyte-endothelium cell adhesion in rat mesenteric venules.Gastroenterology. 1994;106:1271-1276
30.
Olaison G,Smedh K,Sjodahl R..Natural course of Crohn's disease after ileocolonic re-section-endoscopically visualized ileal ulcers preceding surgery.Gut. 1992;33:331-335
31.
Rutgeerts P,Hiele M,Geboes K,Peeters M,Pennickx F..Controlled trial of metronidazole for the prevention of Crohn's recurrence after ileal resection.Gastroenterology. 1995;108:1617-1621
32.
Prantera C,Kohn A,Zannoni F,Spimpolo N,Bonfa M..Metronidazole plus ciprofloxacin in the treatment of active, refractory Crohn's disease: results of an open study.J Clin Gastroenterol. 1994;19:79-88
33.
33.PranteraCZannoniFScribanoMBertoEAndreoliA.An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole and ciprofloxacin. Am J Gastroenterol1996; 328–332.
34.
Moses Pl,Moore Br,Ferrentino N,Bensen Sp,Vecchio Ja..Inflammatory bowel disease 2. Current and future therapeutic options.Postgrad Med. 1998;103 (5): 86-102
35.
Graham Dy,Al-Assi Mt,Robinson M..Prolonged remission in Crohn's disease following therapy for mycobacterium paratuberculosis infection.Gastroenterology. 1995;108:A826
36.
Gui Gph,Thomas Prs,Tizard Mlv,Lake J,Sanderson Jd.Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics.J Antimicrob Chemother. 1997;39:393-400
37.
Sandborn Wj..A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate.Am J Gastroenterol. 1996;91 (3): 423-433
38.
Hinterleitner Ta,Petritsch W,Aichbichler B,Fickert P,Ranner G.Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease.Z Gastroenterol. 1997;35 (8): 603-608
39.
Licthtiger S,Present D,Kornbluth A,Gelernt I,Bauer J.Cyclosporine in severe ulcerative colitis refractory to steroid therapy.N Engl J Med. 1994;330 (26): 1841-1845
40.
Taylor Rb.Difficult Medical Management. Philadelphia, PA: Saunders; 1991:
41.
Oren R,Moshkowitz M,Odes S,Becker S,Keter D.Methotrexate in chronic active Crohn's disease: a double-blind, randomized Israeli multicenter trial.Am J Gastroenterol. 1997;92 (12): 2203-2209
42.
Feagan Bg,Rochon J,Fedorak Rn,Irvine Ej,Wild G.Methotrexate for the treatment of Crohn's disease: The North American Crohn's Study Group Investigators.N Engl J Med. 1995;332 (5): 292-297
43.
Rogler G,Andus T..Cytokines in inflammatory bowel disease.World J Surg. 1998;22:382-389
44.
Radema Sa,Van Dullemen H.,Mevissen M,Jansen J,Tytgat GnjCytokine production, immune activation, and neutrophil migration in inflammatory bowel disease [dissertation]. Amsterdam: University of Amsterdam; 1996:
45.
45.Remicade® (infliximab) professional prescribing information.Centocor Corporation, Malvern, PA, Aug1998.
46.
Targan Sr,Hanauer Sb,Van Deventer Sjh,Mayer L,Present Dh.A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-α for Crohn's disease.N Engl J Med. 1997;337 (15): 1029-1035
Stack Wa,Mann Sd,Roy Aj,Heath P,Sopwith M.Randomized controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease.Lancet. 1997;349 (9051): 521-524
50.
Van Zee Kj,Moldaruer Ll,Oldenburg Hs,Thompson Wa,Stackpole Sa.Protection against lethal Escherichia coli bacterium in baboons (Papioanubis) by pretreatment with a 55 kDa TNFa receptor (CD120a)-IgG infused protein, Ro 45––2081.J Immunol. 1996;156:221-230
51.
Bauditz J,Haemling J,Orther M,Lochs H,Raedler A.Treatment with tumour necrosis factor inhibitor oxpentofylline does not improve corticosteroid dependent chronic active Crohn's disease.Gut. 1997;40 (4): 470-474
52.
Albrecht H,Schook Lb,Jongeneel Cv..Nuclear migration of NF-kappa B correlates with TNF-alpha mRNA accumulation.J Inflamm. 1995;45:64-71
53.
Kucharzik T,Lugering N.,Adolf M,Domschke W,Stoll R..Synergistic effect of immunoregulatory cytokines on peripheral blood monocytes from patients with inflammatory bowel disease.Dig Dis Sci. 1997;42 (4): 805-812
54.
Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease.Gastroenterology. 1997;113:383-389
55.
Chernoff Ae,Granowitz Ev,Shapiro L,Annier E,Lonnemen G.A randomized controlled trial of rIL-10 in humans. Inhibition of inflammatory cytokine production and immune responses.J Immunol. 1995;154:5492-5499
56.
Cominelli F,Nast Cc,Duchini A,Lee M..Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis.Gastroenterology. 1992;103:65-71
57.
Sartor Rb..Cytokines in intestinal inflammation: pathophysiological and clinical considerations.Gastroenterology. 1994;106:533
58.
Eigler A,Siegmund B,Emmerich U,Baumann Kh,Hartmann G..Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production.J Leukoc Biol. 1998;63:101-107
59.
Dignass Au,Podolsky Dk..Interleukin 2 modulates intestinal epithelial cell function in vitro.Exp Cell Res. 1996;225:422
60.
Roth Ad,Kirkwood Jm..New clinical trials with interleukin-2: rationale for regional administration.Nat Immun Cell Growth Reg. 1989;8:153
61.
Murata Y,Ishiguro Y,Itoh J,Munakata A,Yoshida Y..The role of proinflammatory and immunoregulatory cytokines in the pathogenesis of ulcerative colitis.J Gastroenterol. 1995;30:56
62.
Deusch K,Mauthe B,Reiter C,Riethmuller G,Classen M..CD-4 antibody treatment of in flammatory bowel diseases.Gastroenterology. 1993;104:A691
63.
Stronkhorst A,Radema S,Yong Sl,Bijil H,Ten Berge Ijm.CD4 antibody treatment in patients with active Crohn's disease: a phase I dose finding study.Gut. 1997;40 (3): 320-327
64.
Snapper Sb,Syngal S,Friedman Ls..Ulcerative colitis and colon cancer: more controversy than clarity.Dig Dis. 1998;16:81-87
65.
Jain Sk,Peppercorn Ma..Inflammatory bowel disease and colon cancer: a review.Dig Dis. 1997;15 (4––5): 243-252
66.
Eckbom A,Hemlick C,Zack M,Adami H..Increased risk of left bowel cancer in Crohn's disease with colonic involvement.Lancet. 1990;336:357-359
67.
Inflammatory bowel disease.Pharm J. 1990;244 (Jun2): 658-659
